creating and capturing value with biomarkers

5 September 2014 S4998-P-634 v1.0

Capturing and creating value with biomarkers

Dean Griffiths PhD

ACI Biomarker Utilisation & Commercialisation conference

5 September 2014 S4998-P-634 v1.02

Introduction to Cambridge Consultants - A world leader in technology and product innovation

Established out of The University of Cambridge in 1960 Approximately 430 scientists and engineers For clients globally, we

– design and develop breakthrough products

– create and license intellectual property

– provide business consulting in technology critical issues

5 September 2014 S4998-P-634 v1.03

Summary

Understand user needs

Solutions require biomarker and platform

Enable solutions which scale

5 September 2014 S4998-P-634 v1.04Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.05

Researchers, clinicians and consumers

5 September 2014 S4998-P-634 v1.06

Data, therapies and advice

5 September 2014 S4998-P-634 v1.07Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.08

Creating value by aligning to user needs

5 September 2014 S4998-P-634 v1.09

Creating value by aligning to user needs

Biomarkers are not new;

"Shushrut statue" by Alokprasad at en.wikipedia

5 September 2014 S4998-P-634 v1.010

Creating value by aligning to user needs

The need for biomarkers is growing as more targeted cancer therapies increase their market share

Reproduced from (Aitken, 2014)

5 September 2014 S4998-P-634 v1.011

16%

48%

37% Drugs with FDA-approved CDx

Drugs with FDA-approved biomarkers

Other Drugs

Creating value by aligning to user needs

Although many targeted cancer therapies still lack biomarkers

2008 2013

13%

57%

30%

Cambridge Consultants analysis 2014

5 September 2014 S4998-P-634 v1.012

Creating value by aligning to user needs

5 September 2014 S4998-P-634 v1.013

Creating value by aligning to user needs

5 September 2014 S4998-P-634 v1.014

Creating value by aligning to user needs

Where are the tumour cells?

Folate receptor-α targeted fluorescent agent

Van Dam et al Nature Medicine 17, 1315–1319 (2011)

5 September 2014 S4998-P-634 v1.015

Creating value by aligning to user needs

Where are the tumour cells?

Folate receptor-α targeted fluorescent agent

Van Dam et al Nature Medicine 17, 1315–1319 (2011)

5 September 2014 S4998-P-634 v1.016

Creating value by aligning to user needs

Biomarkers used in vivo can detect more tumours

Van Dam et al Nature Medicine 17, 1315–1319 (2011)

5 September 2014 S4998-P-634 v1.017

Creating value by aligning to user needs

Multiple companies are already active in this space

5 September 2014 S4998-P-634 v1.018Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.019

Enabling user adoption

5 September 2014 S4998-P-634 v1.020

Enabling user adoption

Demonstrate utility

Image: Illumina

5 September 2014 S4998-P-634 v1.021

Enabling user adoption

Enable users to be able to access the platform and biomarkers

The Economist

5 September 2014 S4998-P-634 v1.022

Enabling user adoption

Ensure that the platform and biomarker are easy to use and interpret

Image: Illumina

5 September 2014 S4998-P-634 v1.023

Enabling user adoption

Information not just data

Image: Illumina

5 September 2014 S4998-P-634 v1.024Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.025

Scaling user adoption

Scale is king

5 September 2014 S4998-P-634 v1.026

Scaling user adoption

5 September 2014 S4998-P-634 v1.027

Scaling user adoption

Decrease barriers to entry

Image: Abcam

5 September 2014 S4998-P-634 v1.028

Scaling user adoption

Increase data confidence

Image: Abcam

5 September 2014 S4998-P-634 v1.029

Scaling user adoption

Generate publicity and goodwill

Image: Abcam

5 September 2014 S4998-P-634 v1.030Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.031

Where next for biomarkers

New analytes

Image: Senior Airman Sandra Welch

5 September 2014 S4998-P-634 v1.032

Where next for biomarkers

Non-invasive

5 September 2014 S4998-P-634 v1.033

Where next for biomarkers

Predictive

Image: Sgt Eric T. Sheler - USAF

5 September 2014 S4998-P-634 v1.034Commercially Confidential

Agenda

6 Summary

5 Where next for biomarkers

4 Scaling user adoption

3 Enabling user adoption

2 Creating value by aligning to user needs

1 How do users benefit from biomarkers?

5 September 2014 S4998-P-634 v1.035

Summary

Understand user needs

Solutions require biomarker and platform

Enable solutions which scale

5 September 2014 S4998-P-634 v1.0

Cambridge UK

Registered No. 1036296 England

Cambridge Consultants is part of the Altran group, a global leader in Innovation. www.Altran.com

www.CambridgeConsultants.comThe contents of this presentation are commercially confidential and the proprietary information of Cambridge Consultants © 2014 Cambridge Consultants Ltd. All rights reserved.

Boston USA Singapore

Dean.Griffiths@Cambridgeconsultants.com

+44 1223 392139